$2.38 Billion is the total value of Flagship Pioneering Inc.'s 35 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRNA | Moderna Inc | $1,523,857,000 | -17.2% | 12,886,743 | 0.0% | 64.14% | -7.5% | |
| SANA | Sana Biotechnology Inc | $205,434,000 | -6.7% | 34,239,018 | 0.0% | 8.65% | +4.3% | |
| MCRB | Buy | Seres Therapeutics Inc | $148,411,000 | +200.9% | 23,117,045 | +60.8% | 6.25% | +236.2% |
| Omega Therapeutics Inc | $140,391,000 | +42.6% | 25,902,269 | 0.0% | 5.91% | +59.4% | ||
| FHTX | Foghorn Therapeutics Inc | $108,744,000 | -36.9% | 12,674,120 | 0.0% | 4.58% | -29.5% | |
| EVLO | Evelo Biosciences Inc | $105,393,000 | -0.9% | 50,427,328 | 0.0% | 4.44% | +10.7% | |
| DNLI | Denali Therapeutics Inc | $80,407,000 | +4.3% | 2,619,968 | 0.0% | 3.38% | +16.5% | |
| AXLA | Axcella Health Inc | $32,264,000 | -15.8% | 18,867,785 | 0.0% | 1.36% | -5.9% | |
| RUBY | Rubius Therapeutics Inc | $16,557,000 | -49.4% | 38,506,526 | 0.0% | 0.70% | -43.5% | |
| New | Syros Pharmaceuticals Inc | $6,400,000 | – | 993,848 | +100.0% | 0.27% | – | |
| SGTX | Sigilon Therapeutics Inc | $5,185,000 | -39.8% | 10,370,369 | 0.0% | 0.22% | -32.7% | |
| CDAK | Buy | Codiak Biosciences Inc | $2,762,000 | -63.2% | 3,540,636 | +35.8% | 0.12% | -59.0% |
| SYRS | Exit | Syros Pharmaceuticals Inc | $0 | – | -2,938,494 | -100.0% | -0.11% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Flagship Ventures Fund V General Partner LLC #1
- Flagship Ventures Fund IV General Partner LLC #2
- Noubar Afeyan #3
- Flagship Opportunities Fund I General Partner LLC #4
- Flagship Pioneering Special Opportunities Fund II General Partner LLC #5
- Nutritional Health Fund LTP General Partner LLC #6
- Flagship Pioneering Fund VI General Partner LLC #7
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
| DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
| SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
| MODERNA INC | 20 | Q3 2023 | 76.9% |
| EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
| RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
| Axcella Health Inc | 17 | Q2 2023 | 3.5% |
| KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
| Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
| Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| 4 | 2023-08-15 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-07-13 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-02-27 |
| 13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.